ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

Treatment with radiation alone (3×2 Gy) reduced cell proliferation although this did not reach statistical significance ( P =0.14).

also in 61,332 other papers

Encouragingly, no significant difference was apparent between the weight-loss observed in mice receiving only ZD1839 and those receiving the combined treatment ( Table 1 ).

also in 400 other papers

ZD1839 combined with either single or fractionated radiotherapy in mice bearing LoVo tumour xenografts, also produced a highly significant increase in tumour growth inhibition ( P ⩽0.001) when compared to treatment with either modality alone.

also in 75,794 other papers